Elspeth Morrison Beauchamp

  • 914 Citations
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research Interests

Dr. Beauchamp's research has focused on developing drugs for non-traditional targets through inhibiting protein-protein interactions in order to affect cellular function and target cancer cells. Current work is investigating novel interactors with mTORC components in order to developing novel therapeutic strategies that target the mTOR pathways in myeloid leukemias.

Education/Academic qualification

PhD, Georgetown University

… → 2010

Research interests

  • Biochemistry: Proteins
  • Blood Cancer (leukemia and lymphomas)
  • Cancer Biology
  • Drug Discovery
  • Signal Transduction

Fingerprint Dive into the research topics where Elspeth Morrison Beauchamp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 11 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Medulloblastoma Medicine & Life Sciences
Ewing's Sarcoma Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Sirolimus Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2013 2024

Cyclin-Dependent Kinase 9
Protein Transport
Acute Myeloid Leukemia
Protein Biosynthesis
Job Description
Molecular Biology

Research Output 2008 2019

  • 914 Citations
  • 22 Article
  • 2 Comment/debate
  • 1 Review article

Discovery of novel Mnk inhibitors using mutation-based induced-fit virtual high-throughput screening

Mishra, R. K., Clutter, M. R., Blyth, G. T., Kosciuczuk, E. M., Blackburn, A. Z., Beauchamp, E. M., Schiltz, G. E. & Platanias, L. C., Oct 1 2019, In : Chemical Biology and Drug Design. 94, 4, p. 1813-1823 11 p.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
4 Citations (Scopus)

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Beauchamp, E. M., Abedin, S. M., Radecki, S. G., Fischietti, M., Arslan, A. DI., Blyth, G. T., Yang, A., Lantz, C., Nelson, A., Goo, Y. A., Akpan, I., Eklund, E. A., Frankfurt, O., Fish, E. N., Thomas, P. M., Altman, J. K. & Platanias, L. C., Jan 1 2019, In : Blood. 133, 11, p. 1171-1185 15 p.

Research output: Contribution to journalArticle

Cyclin-Dependent Kinase 9
Acute Myeloid Leukemia
Chemical activation

Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma

Eckerdt, F., Clymer, J., Bell, J. B., Beauchamp, E. M., Blyth, G. T., Goldman, S. & Platanias, L. C., Dec 1 2019, In : Scientific reports. 9, 1, 12822.

Research output: Contribution to journalArticle

Open Access
Phosphatidylinositol 3-Kinases
Antineoplastic Agents
Neoplastic Stem Cells
1 Citation (Scopus)

Potent antineoplastic effects of combined PI3Kα-MNK inhibition in medulloblastoma

Eckerdt, F. D., Bell, J. B., Beauchamp, E. M., Clymer, J., Blyth, G. T., Kosciuczuk, E. M., Ma, Q., Chen, D. Z., Horbinski, C. M., Goldman, S., Munshi, H. G., Hashizume, R. & Platanias, L. C., Jun 1 2019, In : Molecular Cancer Research. 17, 6, p. 1305-1315 11 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Antineoplastic Agents
Neoplastic Stem Cells
8 Citations (Scopus)

Differential response of glioma stem cells to arsenic trioxide therapy is regulated by MNK1 and mRNA translation

Bell, J. B., Eckerdt, F., Dhruv, H. D., Finlay, D., Peng, S., Kim, S., Kroczynska, B., Beauchamp, E. M., Alley, K., Clymer, J., Goldman, S., Cheng, S. Y., James, C. D., Nakano, I., Horbinski, C., Mazar, A. P., Vuori, K., Kumthekar, P., Raizer, J., Berens, M. E. & 1 others, Platanias, L. C., Jan 2018, In : Molecular Cancer Research. 16, 1, p. 32-46 15 p.

Research output: Contribution to journalArticle

MAP Kinase Kinase 1
Protein Biosynthesis
Stem Cells